IBRX
A bad week gets messier
ImmunityBio just added a lawsuit to its headache stack. Hagens Berman says it’s investigating a securities class action tied to FDA criticism of claims made about Anktiva, the company’s lead biologic product.
Why investors care
This isn’t just legal theater. The complaint points to a stretch between Jan. 19 and Mar. 24, 2026, and says the FDA warned the company that statements about Anktiva’s efficacy were misleading. The market didn’t exactly shrug that off — ImmunityBio shares fell more than 21% on Mar. 24.
The real risk here
When a biotech gets flagged by regulators over how it talks about a drug, you get a double whammy:
- credibility takes a hit
- the stock can stay stuck in legal quicksand for months
And yes, the lawsuit is still at the “please call our law firm if you lost money” stage. But that’s often where the drama starts, not where it ends.
Big picture
For a clinical-stage biotech, trust is basically currency. If the FDA thinks the pitch is fluffier than the science, investors tend to price in a lot more than just a bad headline.